Pilloxa

News

Pilloxa raises 5,6 MSEK from prominent angel investors.

9 Oct, 2018

Pilloxa has successfully raised 5,6 MSEK from swedish angel investors, ranging from the previous Global Marketing Director at Spotify Sophia Bendz, the previous CEO of Ratos Susanna Campbell, the founder of Serendipity Innovations Saeid Esmaeilzadeh and the business angel Eva Redhe.

The funding will be utilized to clinically validate the product together with some of the most prominent hospitals in the Stockholm region.

For more info, see (in Swedish): https://digital.di.se/artikel/stjarninvesterare-flockas-runt-digital-pillerlada

Pilloxa receives funding from the european EIT Health!

12 Jul, 2018

Pilloxa is one of the 10 companies in Scandinavia that was awarded the EIT Health Headstart funding of € 50 000. EIT Health is the life science division of EIT which is an EU organization that spurs innovation and entrepreneurship across Europe to overcome some of its greatest challenges. The funds will be used to further verify Pilloxa in a clinical context together with transplanted patients. For additional info about the news and about EIT Health, click here EIT Health

Pilloxa receives funding from Vinnova!

25 May, 2018

Pilloxa is one of the companies awarded a grant from the Swedish innovation agency Vinnova. (article in swedish)

Out of 138 applicants, Pilloxa is one of the companies that was awarded funding from the Swedish innovation agency Vinnova. The funds from “Innovationsprojekt i företag” will be used to verify the business model of Pilloxa in a clinical context. For additional info see the following link (in swedish): Vinnova

Pilloxa mentioned on the Stockholm County Council Innovation as one of the most inspirational innovation cases.

1 Mar, 2018

The healthcare organization in Stockholm, Stockholm County Council (SLL) has an innovation division where they list inspirational cases of innovations that have spun out of SLL. Pilloxa is listed as the first project on this list and have also received funding two times from the innovation fund within SLL. For more info, see the following link (in swedish): http://sllinnovation.se/inspiration

Pilloxa receives CE-marking

2 Jan, 2018

Pilloxa has received a certificate of registration from the Swedish Medical Products Agency (Läkemedelsverket). Pilloxa is now marked as a medical device class I and can therefore now be marketed in the EU.